The latest price target for MoonLake (NASDAQ:MLTX) was reported by RBC Capital on March 18, 2025. The analyst firm set a price target for $67.00 expecting MLTX to rise to within 12 months (a possible 67.25% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for MoonLake (NASDAQ:MLTX) was provided by RBC Capital, and MoonLake initiated their outperform rating.

The last upgrade for MoonLake Immunotherapeutics happened on January 17, 2025 when Goldman Sachs raised their price target to $82. Goldman Sachs previously had a neutral for MoonLake Immunotherapeutics.

The last downgrade for MoonLake Immunotherapeutics happened on August 26, 2024 when Wolfe Research changed their price target from N/A to N/A for MoonLake Immunotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MoonLake, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MoonLake was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.

While ratings are subjective and will change, the latest MoonLake (MLTX) rating was a initiated with a price target of $0.00 to $67.00. The current price MoonLake (MLTX) is trading at is $40.06, which is within the analyst’s predicted range.